Topic:

Partnering

Latest Headlines

Latest Headlines

ImmunoGen strikes $440M ADC deal with Takeda

ImmunoGen has struck a $440 million antibody-drug conjugate licensing deal with Takeda, moving it a step closer to recovering from the body blow of last year's Phase III flop. The heavily backloaded deal was cheered by investors.

Google's Calico widens its R&D net with QB3 partnership

Calico, the Google-backed biotech with ambitions to decode the aging process, has aligned itself with California's QB3, a Bay Area brain trust, to further flesh out its R&D mission.

UPDATED: Sun winds up Ranbaxy deal

Sun Pharmaceuticals and Ranbaxy Laboratories have jumped the final hurdle in their merger with government approval of a sale of 7 of their branded drugs to fellow India drugmaker Emcure Pharmaceuticals.

Developer of men's health drug with novel delivery tech secures $1M+ in seed financing

Startup MHB Labs announced the receipt of $1.1 million in seed financing from Romulus Capital and other angel investors in support of its drug delivery technology for convenient administration of a commercially available but little-used medication that could have applications in the men's health space.

GlaxoSmithKline taps Cold Spring Harbor for diabetes R&D

GlaxoSmithKline has reached out to the storied Cold Spring Harbor Laboratory to collaborate on a potential treatment for Type 2 diabetes and obesity, inking a multiyear R&D deal.

UPDATED: ZAI Lab in-licenses BMS cancer candidate

ZAI Lab of Shanghai has in-licensed from Bristol-Myers Squibb China rights to the Phase III liver cancer drug brivanib, an oral kinase inhibitor for oncology indications including hepatocellular carcinoma.

Amgen link strong as Astellas files with PMDA on Evolocumab, and new indication for Kiklin

Japan's Astellas Pharma has filed with Japan's Pharmaceutical and Medical Devices Agency for approval of PCSK9 inhibitor evolocumab for high cholesterol under the Amgen Astellas BioPharma joint venture.

Japan's Meiji Seika ends deal with Amalyte on anti-allergy candidate

Japan's Meiji Seika Pharma has terminated a license deal with U.S.-based Amalyte Pharmaceuticals for its investigational antiallergic drug ME3301 and discontinued development.

Lilly inks a $456M oncology deal with China's Innovent

In a second major bet on Asian R&D, Eli Lilly has signed a $456 million partnership with China's Innovent Biologics to collaborate in oncology, mixing and matching assets with hopes of finding success in each company's home country.

Lilly and China's Innovent Biologics tie up on cancer drug candidates with $56M upfront

Eli Lilly & Co. and China's Innovent Biologics agreed to co-develop at least three experimental cancer drugs--including one from Lilly's research labs and two from Innovent--in a deal that will see the Indianapolis-based company pay $56 million upfront.